Shares of KB Home (NYSE: KBH) increased above 4% after the bell as the Q2 earnings surpassed estimates on the headline numbers. The homebuilder’s stock has recovered 38% from last November where it touched a new 52-week low of $17 mark. The surge in the share price is mainly attributable to solid first-quarter earnings which surpassed estimates.
Thanks to increased revenues from the joint ventures, Financial Services division saw a 14% jump in the top line, offset by 7% drop in the Homebuilding segment. Strong performance in the Financial Services helped KB Home to report top and bottom line beat for the Q2 period.
For the second quarter, analysts were expecting muted performance with revenue of $936 million, a 15% drop from last year and EPS of 40 cents, down 30% from the prior year period.
CEO Jeffrey Mezger commenting on the strong Q2 results said: “We are pleased with our second quarter performance, as we made significant progress on our Returns-Focused Growth Plan. Two of the key objectives of this Plan are to grow our business and strengthen our balance sheet.”
KB Home reiterated that the spring selling season is expected to be strong aided by community growth and improved orders. The second half of the year would benefit from the increase in sales, which is good news for investors.
Even though home deliveries improved 2%, West Coast continues to drag the growth from other regions. The decline in the average selling price of 8% is primarily to lower prices from the West Coast region and increased home deliveries from the low-cost regions.
Net orders and value grew double-digits across all four regions while average net orders per community came in at 5.4 months over 5.5 months in the prior year period. Backlog rose 2% to 5,927 units helped by growth in West Coast and Southeast regions.
Looking Back
In the first quarter, KB Home earnings exceeded analysts’ expectations while the revenue missed estimates due to decline in homebuilding revenue. Net income was $0.31 per share compared to a loss of $0.82 per share last year. However, revenue fell 7% to $811.5 million due to weaker housing sales.
Most Popular
Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO
Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training
INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues
Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came
Riding the AI wave, Nvidia looks set to stay on the high-growth path
After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on
